Lupeol, a dietary triterpene present in many fruits and medicinal plants, has been reported to possess many pharmacological properties including anticancer effect in vitro and in vivo. However, the activity of lupeol against osteosarcoma remains unclear. The present study is conducted to investigate the anticancer activity and the underlying mechanisms of lupeol on human osteosarcoma cells (MNNG/HOS and MG-63) in vitro and in vivo. MNNG/HOS and MG-63 cells were treated by lupeol and subjected to methyl thiazolyl tetrazolium analysis, Hoechst staining, annexin V/propidium iodide double staining, cell cycle analysis, and Western blot analysis. In addition, MNNG/HOS xenograft tumors were established in female nude BALB/c mice, and lupeol was intravenously administered to evaluate the anticancer capacity in vivo. Our results showed that lupeol induced apoptosis as well as cell cycle arrest in G0/G1 phase of MNNG/HOS and MG-63 cells in a dose-dependent manner in vitro. Furthermore, the protein expression levels of phospho-phosphatidylinositol 3-kinase (p-PI3K), phospho-protein kinase B (p-AKT), p-p70S6K, and cyclin D1 were significantly downregulated, whereas the expression levels of p21 and p27 were upregulated. These protein interactions may play a pivotal role in the regulation of apoptosis and cell cycle arrest. More importantly, our in vivo studies showed that administration of lupeol decreased tumor growth in a dose-dependent manner and has no significant effect on the function of liver and kidney. Taken together, our findings indicated that lupeol can induce apoptosis as well as cell cycle arrest of human osteosarcoma cells through phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway and might offer a promising new approach in the effective treatment of osteosarcoma.
Introduction
Osteosarcoma, the most common primary malignant tumor of bone, occurs predominantly in young adults and adolescents. 1, 2 It is characterized by the proliferation of malignant mesenchymal cells that are capable of producing osteoid or immature bone and is associated with high morbidity, early metastasis, and mortality. [3] [4] [5] The treatments of osteosarcoma include surgery, chemotherapy, and radiotherapy but are still unsatisfying. 6 The therapeutic modality that is currently favored involves neoadjuvant chemotherapy, followed by surgery, surgical resection, and chemotherapy again following surgery, and the 5-year survival of patients with osteosarcoma has increased to 60% to 70% through the use of such protocols. 7 Although new therapies have been used, the inductions of drug-resistant and unwanted side effects are involved in chemotherapy, which inadequately treats the disease. 8 This disappointing outcome strongly suggests that novel agents are urgently needed for the treatment of osteosarcoma and improve its prognosis. Nowadays, to discover and develop novel natural compounds that have therapeutic selectivity or that can preferentially kill cancer cells with little toxicity or few side effects to normal cells is an important tendency for cancer therapy. 9 Lupeol (Lup-20(29)-en-3b-ol; Figure 1 ), a dietary triterpene found in several medicinal plants and in various fruits such as olive, strawberry, grapes, mango, figs and vegetables, is used for the treatment of number of ailments in North America, Latin America, China, Japan, and Caribbean. [10] [11] [12] Lupeol has attracted much attention because of its low toxicity and wide pharmacological effects. Extensive research over the past decades have revealed various important pharmacological activities of lupeol, including antiarthritis, anti-inflammation, antidiabetes, antiheart diseases, antirenal toxicity, and antihepatic toxicity. [13] [14] [15] Recently, lupeol has been extensively studied for their cancer chemopreventive potential against various cancers, such as hepatocellular carcinoma, 16 prostate cancer, 17 skin cancer, 18 epidermoid carcinoma, 19 and melanoma. 20 However, there has no research reported to date to evaluate the chemotherapeutic potential and mechanism of lupeol in the management of osteosarcoma.
The goals of this study were to determine whether lupeol could inhibit the growth and induce apoptosis as well as cell cycle arrest of human osteosarcoma MNNG/HOS and MG-63 cells and, if so, to clarify the related mechanisms, which may offer a promising new approach in the effective treatment of human osteosarcoma.
Materials and Methods

Reagents and Antibodies
Lupeol was purchased from Sigma-Aldrich (St Louis, Missouri), and a stock solution of lupeol (30 mmol/L) was prepared by resuspension in warm alcohol and dilution in dimethyl sulfoxide (DMSO) at 1:1 ratio. The final lupeol concentrations used for the different experiments were prepared by diluting the stock solution with complete cell culture medium. Materials used included 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT; Sigma Chemical Company, St Louis, Missouri), annexin V-fluorescein isothiocyanate (FITC) apoptosis detection kit (MultiSciences Biotech, Shanghai, China), Hoechst 33258 staining assay kit (Molecular Probes, Beyotime Institute of Biotechnology, Shanghai, China), glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibodies (Kangchen Bio-tech, Shanghai, China), phosphatidylinositol 3-kinase (PI3K), p-PI3K, total-AKT, p-AKT (Thr308), mammalian target of rapamycin (mTOR), phospho-mammalian target of rapamycin (p-mTOR), P70S6K, p-P70S6K, cyclin D1, p27, p21, horseradish peroxidase-conjugated sheep antimouse immunoglobulin (Ig) G, and sheep antirabbit IgG antibodies (Cell Signaling Technology, Danvers, Massachusetts).
Cell Lines and Culture
The human osteosarcoma cell lines MNNG/HOS and MG-63 were obtained from Cell Bank of Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China), where they were tested and authenticated. The cells were cultured in Eagle minimum essential medium, supplemented with 10% fetal calf serum, 100 units/mL penicillin, and 100 mg/mL streptomycin, and incubated in a humidified atmosphere with 5% CO 2 at 37 C. The cells were kept in an exponential growth phase during experiments.
Cell Proliferation Assay
The MTT assay was used to examine the viability of human osteosarcoma cells treated with lupeol. Cells were trypsinized and seeded into 96-well plates at a density of 6 Â 10 3 cells per well. The cells were cultured overnight to allow attachment and then replaced with fresh medium containing various concentrations (0-120 mmol/L) of lupeol. At different time points (24, 36 , and 48 hours), 20 mL MTT (5 mg/mL) was added to each well followed by 4-hour incubation. Then, the medium was discarded, and 150 mL DMSO was added to each well to dissolve the resulting formazan crystals. The absorbance values at 492 nm were measured. Data were collected from 3 separate experiments, and the effect on cell growth inhibition was assessed as percentage of cell proliferation inhibition, wherein vehicle-treated cells were taken as 0% inhibition.
Hoechst Staining
The apoptosis of MNNG/HOS and MG-63 cells treated with lupeol was determined by Hoechst staining. Briefly, the cells were exposed to lupeol (15, 30, and 60 mmol/L) for 36 hours and then stained with Hoechst 33258 (10 mg/mL) for 10 minutes. After being washed with phosphate-buffered saline (PBS), they were observed using an inverted fluorescence microscope. Live cell nuclei showed dispersion and uniform fluorescence, while dead cells were not stained with Hoechst. Apoptotic cells were characterized by nuclear shrinkage, condensation, and fragmentation. Cells from 5 randomly selected microscopic fields were counted. The apoptosis index (AI) of cells was calculated using the following formula: AI (%) ¼ apoptotic cells/total cells Â 100%.
Annexin V-FITC/PI Staining
Annexin V-FITC/propidium iodide (PI) double staining was used to quantify the apoptotic rate of MNNG/HOS and MG-63 cells treated with lupeol. Briefly, cells were seeded into 6-well plates at 2 Â 10 5 cells/well and exposed to lupeol (15, 30 , and 60 mmol/L) for 36 hours. The cells were then stained using annexin V-FITC/PI double fluorescence apoptosis detection kit following the manufacturer's instruction. After incubation for 15 minutes at room temperature in the dark, the cells were analyzed using flow cytometry (Becton Dickinson, Franklin Lakes, New Jersey) within 1 hour after the staining.
Cell Cycle Analysis
Cell cycle was measured by PI, which can label cellular nuclear DNA. After treating with lupeol (0, 15, 30, and 60 mmol/L) for 36 hours, MNNG/HOS and MG-63 cells were harvested by centrifugation, rinsed 3 times with sterile PBS, and fixed in ice-cold 70% ethanol at 4 C overnight. After centrifugation at 1500g for 3 minutes, the cells were dyed with PI and incubated for 30 minutes in the dark. Cell cycle was analyzed by Becton Dickinson FACScan. The ratio of cells in the G0/G1, S, and M phases of the cell cycle was decided by their DNA content.
Western Blot Analysis
MNNG/HOS and MG-63 cells were treated with lupeol (0, 15, 30, and 60 mmol/L) for 36 hours, respectively. Then, the cellular proteins were extracted in lysis buffer (1% NP-40, 0.1% sodium dodecyl sulfate [SDS], 0.5% sodium deoxycholate, 150 mmol/L NaCl, and 10 mmol/L Tris-HCl) containing 1/ 100 phenylmethanesulfonyl fluoride solution. Proteins were separated by SDS-polyacrylamide gel electrophoresis and transferred onto polyvinylidene fluoride membrane (Beyotime Institute of Biotechnology). Nonspecific binding sites were blocked by incubating with Tris-buffered saline with Tween (TBST) containing 5% (wt/vol) nonfat dried milk for 2 hours at room temperature. The membranes were incubated with primary antibodies overnight at 4 C and then with appropriate secondary antibodies conjugated to horseradish peroxidase for 1 hour at room temperature. After each incubation period, the membranes were washed thrice with TBST, each for 5 minutes. Signals were visualized by electrochemiluminescence. Equal protein loading was assessed by the expression of GAPDH. The bands were semiquantified using Image J software (National Institutes of Health, Bethesda, Maryland).
Animal Experiment
Female BALB/c nude mice at 4 weeks of age (Shanghai SLAC Laboratory Animal Center of Chinese Academy of Sciences, Shanghai, China) were maintained under specific pathogenfree environment. Exponentially growing MNNG/HOS cells (5 Â 10 6 ) were suspended in 200 mL PBS and subcutaneously injected into the right axillary fossa of each nude mouse under aseptic conditions. On day 7, 40 nude mice whose tumors were similar in size (6-8 mm in diameter) were chosen, and equal numbers were assigned to 4 groups (n ¼ 10 per group). Then, the treatment groups were injected intravenously with 2 doses of lupeol (30 and 60 mg/kg) on alternative days, respectively. Positive and negative control group animals were given cyclophosphamide (CTX) 25 mg/kg and sterile physiological saline, respectively. After 2 weeks of drug administration, all mice were killed on day 23, and tumors were dissected and weighed. The tumor volume was calculated using the formula ''0.5 Â a Â b 2 ,'' in which a and b represent the maximal and minimal diameters. The tumor inhibition ratio was expressed according to the following formula: ([mean tumor weight of the control group À mean tumor weight of the treated group]/the mean tumor weight of the control group) Â 100%. The animal studies were approved by the Wujiang No. 1 People's Hospital Ethics Committee, and the principles of laboratory animal care were followed in all animal experiments.
Cytotoxicity Assay
Blood of mice was collected in heparin-coated tubes just before they were killed. Plasma isolated from each group was subjected to analysis of a panel of hepatic function tests (aspartate aminotransferase [AST], alanine aminotransferase [ALT], albumin [ALB]) and kidney function tests (blood urea nitrogen [BUN] and serum creatinine [Scr]). All assays were performed using kits from Bioassay Systems (Bay Area, San Francisco), and all assays were performed according to the manufacturer's instructions.
Statistical Analysis
All data are expressed as mean + standard deviation (SD) and analyzed by the SPSS (International Business Machines Corporation, State of New York) 17.0 software. Comparisons among different groups were performed using 1-way analysis of variance, and a P value less than .05 was considered statistically significant. All experiments presented here derived from at least 3 independent experiments.
Results
Lupeol treatment inhibited the growth and proliferation of MNNG/HOS and MG-63 cells. MNNG/HOS and MG-63 cells
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Technology in Cancer Research & Treatment 15 (6) were incubated with lupeol at various concentrations for 24 to 48 hours, and we found that the growth and proliferation of human osteosarcoma cells decreased in a time-dependent manner ( Figure 2 ). The results showed that at the concentration of 0 to 60 mmol/L of lupeol, the inhibition rate sharply increased. However, higher concentration of lupeol had a saturated inhibitory effect. During the following experiment at 36 hours, lupeol showed a significantly higher inhibiting effect than that at 24 hours. In contrast, there was no significant difference in cell inhibition rate among prolonged treatment for 48 hours. For MNNG/HOS and MG-63 cells, the half maximal inhibitory concentration (IC50) for lupeol at 36 hours was 36.8 and 52.3 mmol/L, respectively. Based on these observations, we selected a dose of 15 to 60 mmol/L and a period of 36 hours postlupeol treatment for further studies.
Lupeol Treatment Induced Apoptosis of MNNG/HOS and MG-63 Cells
The fastest way to detect apoptosis is the observation of variations in nucleus morphology of incubated cells using Hoechst staining. In the present study, morphological changes in the apoptotic cells were revealed by the Hoechst 33258 staining ( Figure 3A, B ). In the untreated MNNG/HOS and MG-63 cells, the nuclei were stained weakly homogeneously blue, whereas in the group treated with different concentrations of lupeol, the cells exhibited strong blue fluorescence and cell nuclei appeared to be highly condensed and crescent shaped, revealing the typical apoptosis characteristics. Next, we quantified lupeol-induced apoptosis of human osteosarcoma cells by flow cytometry assay. The apoptotic rates of the MNNG/HOS cells were 28.90% + 3.99%, 47.62% + 4.47%, and 67.10% + 5.65% after treatment with 15, 30, and 60 mmol/L lupeol, respectively, which were all higher than that of the untreated cells (8.53% + 2.76%; P < .05). The apoptotic rates of the MG-63 cells were 25.23% + 4.35%, 38.60% + 5.16%, and 60.37% + 4.64% after treatment with 15, 30, and 60 mmol/L lupeol, respectively, which were all higher than that of the untreated cells (7.01% + 2.65%; P < .05; Figure 3C , D). These data suggested that lupeol induced apoptosis of MNNG/HOS and MG-63 cells dose dependently.
Lupeol Treatment Induced Cell Cycle Arrest of MNNG/HOS and MG-63 Cells
We next investigated the cell cycle distribution of MNNG/ HOS and MG-63 cells treated with different concentrations of lupeol (0, 15, 30, and 60 mmol/L) for 36 hours using PI staining assay. We found that compared with the untreated controls, the fraction of MNNG/HOS and MG-63 cells at the G0/G1 phase was significantly increased (P < .05) in the lupeol-treated cells in a dose-dependent manner (Figure 4) . To elucidate the mechanisms accounting for the cell cycle arrest by lupeol, we examined the expression of regulators of the G1/S phase transition. The Western blot analysis showed that the protein levels of cyclin D1 were significantly downregulated, whereas the levels of p21 and p27 were significantly upregulated (P < 0.05) in the lupeol-treated cells compared with the control group ( Figure 5A-C) . Furthermore, the change in protein levels of cyclin D1, p21, and p27 after treatment with lupeol showed a dose-dependent manner and thus blocked the cells from G1 to S phase. 
Lupeol Suppressed the Activation of PI3K/AKT/mTOR Pathway in MNNG/HOS and MG-63 Cells
To investigate the possible molecular mechanisms responsible for lupeol-induced apoptosis in MNNG/HOS and MG-63 cells, we evaluated the protein expression of PI3K, p-PI3K, protein kinase B (AKT), p-AKT, mTOR, p-mTOR, p70S6K, and p-p70S6K in cells incubated for 36 hours with different concentrations of lupeol (15, 30 , and 60 mmol/L). The results revealed that the expression levels of PI3K, AKT, mTOR, and p70S6K in the lupeol treatment groups were not significantly different from that in the control group, while the expression levels of p-PI3K, p-AKT, p-mTOR, and p-p70S6K were significantly reduced in a dose-dependent matter compared with the control group (P < .05; Figure 5D -F).
Those all results suggested that lupeol inhibited the activation of PI3K and its downstream signaling molecules.
Lupeol Treatment Inhibited the Tumor Growth In Vivo
We further studied the effects of lupeol on tumor cell growth in vivo. The xenograft model was established in BALB/c nude mice following subcutaneous transplantation of MNNG/HOS cells. As shown in Figure 6A -C, the weight and volume of the transplanted tumors were significantly inhibited after administration of 30 and 60 mg/kg lupeol compared with the negative control group (P < .05), and the inhibitory rates were 30.9% and 60.8%, respectively. The inhibition levels of tumor weight and volume between 30 and 60 mg/kg lupeol-treated groups were also statistically significant (P < .05). The 25 mg/kg CTXtreated mice had the smallest tumor weight and volume among these 4 groups. Further, we determined whether lupeol treatment results in any cytotoxicity when given to the mice with tumors. Plasma isolated from each group was subjected to the analysis of AST, ALT, ALB, BUN, and Scr. As shown in Figure 6D , there was no significant difference between the untreated and the lupeol-treated groups, whereas the expression of ALT in CTX groups was significantly increased when compared with the control group (P < .05).
Discussion
Lupeol has been shown to exhibit various pharmacological activities under in vitro and in vivo conditions, and in the recent years, studies have shown that lupeol can inhibit the proliferation and induce apoptosis of a variety of tumor cells. For instance, Saleem et al 17 found that lupeol could inhibit proliferation of human prostate cancer cells by targeting b-catenin signaling. We have also shown that lupeol could inhibit proliferation and induce apoptosis of human pancreatic cancer proliferating cell nuclear antigen 1 cells through AKT/extracellular signal-regulated kinase (ERK) pathways, 21 and lupeol could induce apoptosis and inhibit invasion in gallbladder carcinoma GBC-SD cells by suppression of epidermal growth factor receptor/matrix metallopeptidase 9 signaling pathway. 22 However, little is known about its effects on human osteosarcoma, and the precise mechanism involved remains largely unknown. Therefore, in this study, we proved the anticancer effects of lupeol on human osteosarcoma MNNG/HOS and MG-63 cells and explored the related molecular mechanisms.
To the best of our knowledge, this is the first study to reveal the ability of the natural compound lupeol on MNNG/HOS and MG-63 cells. Uncontrolled proliferation is a key aspect of tumorigenesis, and inhibiting cell proliferation can achieve growth arrest in tumor cells. Cell apoptosis is an autonomous cell death process, which can be induced by a variety of physical and chemical factors and drugs. 23 During the process, apoptosis is characterized by cell shrinkage, blebbing of the plasma membrane, chromatin condensation, and nuclear condensation without cell lysis. 24 Since deregulation of apoptosis is the hallmark of all cancer cells, the induction of apoptosis has been described as a standard and best strategy in anticancer therapy. 25, 26 Also, it is reported that cell cycle deregulation is one of the major hallmark traits of cancer cells. 27 Clearly, an agent that could efficiently inhibit the proliferation and induce apoptosis as well as cycle arrest of cancer cells would be a hopeful candidate to suppress cancer progression and thus could reduce mortality. Therefore, we examined whether lupeol could inhibit proliferation and induce apoptosis as well as cycle arrest of human osteosarcoma cell lines MNNG/HOS and MG-63. Results from MTT, Hoechst 33258 staining, annexin V-FITC/PI staining, and Western blot analysis suggested that lupeol inhibited the proliferation and induced apoptosis of MNNG/HOS and MG-63 cells in a dose-dependent manner in the range of 15-60 mmol/L and induced cell cycle arrest at G0/G1 phase by upregulating p27 and p21 and downregulating cyclin D1.
To elucidate the molecular mechanisms how lupeol inhibits proliferation and induces apoptosis as well as cell cycle of human osteosarcoma MNNG/HOS and MG-63 cells, we 
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Technology in Cancer Research & Treatment 15 (6) investigated several related protein changes in the lupeoltreated and the nontreated cells. The PI3K/AKT/mTOR signaling pathway has been well documented to play a major role in breast cancer, cervical cancer, lung cancer, and colon cancer, [28] [29] [30] [31] and this pathway represents an attractive target for anticancer therapeutics. Recent clinical studies have reported that activation of the PI3K/AKT/mTOR pathway correlates with tumor progression and reduced patient survival. 32 The PI3K constitutes a lipid kinase family characterized by the capability to phosphorylate inositolring 3'-OH group in inositol phospholipids. 33 It can recruit a subset of signaling proteins with pleckstrin homology domains to the cellular membrane, such as AKT/protein kinase B. AKT kinase, a serine/threonine kinase, is the core component of the PI3K/AKT signaling pathway with numerous downstream molecules, such as caspase, mTOR, p21, p27, p53, and cyclin D1, which regulate cell proliferation, differentiation, apoptosis, autophagy, and cycle. 34, 35 The activation of AKT was positively correlated with cancer stages, indicating that p-AKT is an independent prognostic maker for patients with cancer. Through generating the second messenger phosphatidylinositol-3,4,5-trisphosphate, PI3K indirectly activates the protein kinase mTOR, which contains a PI3K homology domain that regulate cell proliferation, apoptosis, angiogenesis, metabolism, and protein synthesis. 36 The mTOR kinase exists as a component of 2 distinct protein complexes: the mTORC1 complex phosphorylates substrates S6K at Thr389 and EIF4E at Ser209, whereas the mTORC2 complex itself phosphorylates AKT at Ser473. 37 Interestingly, the activation of mTOR and then the phosphorylation of these downstream targets preferentially lead to the translation of messenger RNAs for protumorigenic genes implicated in cell cycle progression, cell differentiation, cell death, and angiogenesis. 38 Based on these findings, the PI3K/AKT/mTOR pathway is believed to be a promising therapeutic target for the treatment of cancer. In this study, we found that after dealing with different concentrations of lupeol, the expression of phosphorylation in PI3K, AKT, mTOR, and p70S6K was significantly decreased at the protein levels in MNNG/HOS and MG-63 cells compared with the control group (P < .05). Those results together with the present reports indicate that PI3K/ AKT/mTOR pathway plays an important role in regulating proliferation and apoptosis of human osteosarcoma cells. Cyclin D1 is an inhibitor of cell cycle and promotes progression from G1 to S phase, its expression is elevated in tumor cells, and it is relevant with abnormal proliferation, invasion, and prognosis of tumor cells. 39 Conversely, p21 and p27 are implicated in the negative regulation of cell cycle progression from G1 to S phase by modulating the activity of cyclindependent kinases. It is reported that AKT could positively regulate cyclin D1 expression and negatively regulate the expression of p21 and p27. 40 Therefore, in this study, we can draw that lupeol induced cell cycle arrest at G1 phase by decreasing cyclin D1 and increasing p21 and p27 through inactivation of AKT.
In addition, in our in vivo study, we found that lupeol (30 and 60 mg/kg) and CTX (25 mg/kg) significantly inhibited the tumors weight and volume during the treatment period. Furthermore, our cytotoxicity assay showed that there was no significant difference between the untreated and the lupeol-treated mice on hepatic function and kidney function, whereas the expression of ALT in CTX groups was significantly increased when compared with the control group (P < .05).
In conclusion, the present investigation confirms that lupeol exerts a significant antiosteosarcoma effect both in vitro and in vivo. Moreover, our data showed that the anticancer activity of lupeol could be attributed to its inhibition of proliferation and induction of apoptosis as well as cycle arrest through the inhibition of the PI3K/AKT/mTOR pathway. The dramatic effects of lupeol in human osteosarcoma cells indicated that lupeol could be recognized to be a useful candidate as chemotherapeutic agent against human osteosarcoma.
